Probert L, Keffer J, Corbella P, Cazlaris H, Patsavoudi E, Stephens S, Kaslaris E, Kioussis D, Kollias G
Laboratory of Molecular Genetics, Hellenic Pasteur Institute, Athens, Greece.
J Immunol. 1993 Aug 15;151(4):1894-906.
To evaluate the biologic potential of T cell-specific TNF production in vivo, we have generated transgenic mice constitutively expressing TNF in their T cell compartment. This was achieved by placing a wild-type or a 3'-UTR modified fragment of the human TNF gene under the influence of the T cell-specific, locus control region of the human CD2 gene. Transgenic mice that express human TNF mRNA in T cells develop marked histologic and cellular changes locally in their lymphoid organs and a lethal wasting syndrome associated with widespread vascular thrombosis and tissue necrosis. The extent of pathologic changes and their time of onset appear to reflect levels of transgene expression. Thus, transgenic lines that express the transgene at high levels show both lymphoid organ and systemic abnormalities with wasting. In one transgenic line, mice express lower levels of the transgene and develop normally despite pronounced local lymphoid organ defects, confirming in vivo, the differential potential of localized and systemic TNF action. All pathologic changes could be neutralized by the administration of mAb specific for human TNF. These results demonstrate the important role of T cell-specific TNF production in the development of specific pathology and provide a means by which to evaluate the role of TNF in thymocyte development. Transgenic mice that express TNF constitutively in the T cell compartment offer a unique in vivo system by which to analyze the molecular character of systemic vs contact-dependent and paracrine modes of TNF action. Furthermore, given the species-specific nature of the mouse p75 TNF receptor, it is assumed that the pathology induced by human TNF in these transgenic mice is associated exclusively with p55 TNF receptor signaling. Conceivably, the differential contribution of each of the two TNF receptors in thymus development and TNF-mediated disease can be assessed by comparison of the biologic potential of human vs mouse TNF in the transgenic system developed.
为了评估体内T细胞特异性产生肿瘤坏死因子(TNF)的生物学潜能,我们构建了在其T细胞区室中组成性表达TNF的转基因小鼠。这是通过将人TNF基因的野生型或3'-非翻译区(UTR)修饰片段置于人CD2基因的T细胞特异性基因座控制区的影响下实现的。在T细胞中表达人TNF mRNA的转基因小鼠在其淋巴器官局部出现明显的组织学和细胞变化,以及与广泛血管血栓形成和组织坏死相关的致死性消瘦综合征。病理变化的程度及其发病时间似乎反映了转基因表达水平。因此,高水平表达转基因的转基因品系显示出淋巴器官和全身异常并伴有消瘦。在一个转基因品系中,小鼠表达较低水平的转基因,尽管局部淋巴器官有明显缺陷,但仍正常发育,这在体内证实了局部和全身TNF作用的不同潜能。所有病理变化都可以通过给予针对人TNF的单克隆抗体来中和。这些结果证明了T细胞特异性产生TNF在特定病理学发展中的重要作用,并提供了一种评估TNF在胸腺细胞发育中作用的方法。在T细胞区室中组成性表达TNF的转基因小鼠提供了一个独特的体内系统,通过该系统可以分析TNF作用的全身与接触依赖性和旁分泌模式的分子特征。此外,鉴于小鼠p75 TNF受体的物种特异性性质,推测这些转基因小鼠中由人TNF诱导的病理学仅与p55 TNF受体信号传导相关。可以想象,通过比较在开发的转基因系统中人TNF与小鼠TNF的生物学潜能,可以评估两种TNF受体在胸腺发育和TNF介导的疾病中的不同贡献。